How much of Atea Pharmaceuticals’ revenue comes from haram?

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics for life-threatening viral infections.

The company’s lead product for treating patients with COVID-19, AT-527, is an orally administered direct-acting antiviral. 

Atea earns its revenue primarily through collaboration agreements with Roche.

Practical Islamic Finance concludes:

None of Atea Pharmaceuticals’ revenue comes from anything inherently haram.

Does Atea Pharmaceuticals rely on interest to operate?

Most Recent Quarter
ended
3/31/2022
Fiscal year
ended
12/31/2021
Fiscal year
ended
12/31/2020
Interest Expense $ $ $
Total Operating Expenses $42,175 $212,990 $59,663
Interest Expense /
Total Operating Expenses
0.00% 0.00% 0.00%
*Numbers in thousands, U.S. dollars

Practical Islamic Finance concludes:

Atea Pharmaceuticals, Inc. most recent quarter indicates no reliance on Riba in its operations.

What is Atea Pharmaceuticals’ Environmental, Social, and Governance (ESG) impact?

Environment

No notable environmental highlights.

Social

Atea Pharmaceuticals has a Glassdoor rating of 3.7 out of 5.0 from over 60 current and previous employees compared to a 3.3 average for all other Glassdoor rated companies.

Governance

No notable governance highlights.

Practical Islamic Finance concludes:

Atea Pharmaceuticals has a net positive ESG impact.

Comfort Rating

From Atea Pharmaceuticals’ business, financial, and ESG reviews, Practical Islamic Finance rates Atea Pharmaceuticals stock as:

Comfortable to invest in from a Halal perspective.

Sources

Atea Reviews 

Atea Pharmaceuticals Q2 2021 10-Q

Atea Pharmaceuticals 2020 10-K